GlassScriptPhysician profile
Lucy Zhou Lee
NPI 1720453020
$3,657.94
in general payments reported to CMS, 2019-2025
32 companies · $870 in 2025
The $870 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $586 · 2022: $292 · 2023: $974 · 2024: $935 · 2025: $870.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,780.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,780.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $707.65 | 2021-2025 | |
| Novo Nordisk INC | $649.29 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $439.53 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Merck Sharp & Dohme LLC | $366.02 | 2021-2025 | Gardasil 9, Vaxneuvance, Capvaxive |
| Pfizer INC. | $342.72 | 2021-2025 | |
| Glaxosmithkline, LLC. | $137.28 | 2021-2025 | Shingrix, Arexvy |
| Amgen INC. | $97.31 | 2023-2025 | Evenity, Prolia, Otezla |
| Biohaven Pharmaceutical Holding Company LTD. | $90.23 | 2022 | |
| Mayne Pharma Commercial LLC | $87.69 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $79.27 | 2021 | |
| Phathom Pharmaceuticals, INC. | $76.94 | 2024-2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.31 | 2024-2025 | Ofev |
| Astrazeneca Pharmaceuticals LP | $60.25 | 2021-2025 | Airsupra |
| Boston Scientific Corporation | $44.98 | 2023 | Wavewriter Alpha Prime 16 |
| Biohaven Pharmaceuticals, INC. | $44.18 | 2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impel Pharmaceuticals INC. | $41.96 | 2023 | Trudhesa |
| Idorsia Pharmaceuticals US INC | $31.43 | 2023 | Quviviq |
| Teleflex LLC | $27.73 | 2025 | Barrigel |
| Alexion Pharmaceuticals, INC. | $23.95 | 2021 | |
| Gilead Sciences, INC. | $23.40 | 2025 | |
| Exeltis, USA INC. | $23.39 | 2023 | Slynd |
| Organon LLC | $23.23 | 2025 | Nexplanon |
| Hologic Sales and Service, LLC | $20.72 | 2023 | Aptima |
| Phadia US INC. | $19.29 | 2025 | Immunocap |
| Exact Sciences Corporation | $18.84 | 2023 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $18.38 | 2024 | |
| Edwards Lifesciences Corporation | $17.33 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Optos, INC. | $16.86 | 2022 | |
| Alnylam Pharmaceuticals INC. | $16.35 | 2023 | Givlaari |
| Eisai INC. | $13.97 | 2021 | |
| Tolmar, INC. | $13.78 | 2025 | Jatenzo |
| Seqirus USA INC | $11.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lucy Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.